Raptiva

Phase 2Small molecule

Roche

Raptiva is one of 78 small molecule programs targeting Discoid Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Discoid Lupus ErythematosusActive, not recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Type 1 DiabetesActive, not recruiting

Discoid Lupus ErythematosusPhase 2

Active, not recruiting

PsoriasisPhase 1/Phase 2

Active, not recruiting

Atopic DermatitisPhase 1

Active, not recruiting

Type 1 DiabetesPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Taltz

Eli Lilly

Preclinical

20 3

Bimzelx

UCB

Preclinical

17 4

Humira

CCelltrion

Preclinical

42 5

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 6

Raptiva

Roche

Phase 2

6 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis6 trials

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

Completed·UUniversity of California, Davis·Phase 1/2·NCT00368654·12 enrolled

A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g

Completed· Roche logo

Roche·Phase 3·NCT00109252

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Completed· Roche logo

Roche·Phase 3·NCT00096603·450 enrolled

Show 3 more trials

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

Completed· Roche logo

Roche·Phase 4·NCT00096980·300 enrolled

A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

Completed· Roche logo

Roche·Phase 3·NCT00109317·686 enrolled

A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis

Completed· Roche logo

Roche·Phase 1·NCT00382512·60 enrolled

Sjogren's Syndrome1 trial

Pilot Study of Raptiva to Treat Sjogren's Syndrome

Terminated·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00344448·10 enrolled

Discoid Lupus Erythematosus1 trial

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

Withdrawn·TThe Cleveland Clinic·Phase 2·NCT00308204

CLE1 trial

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00256139·793 enrolled

Atopic Dermatitis1 trial

Efalizumab for Moderate to Severe Atopic Dermatitis

Completed·OOregon Health and Science University·Phase 1·NCT00226057·10 enrolled

1 more indication

Type 1 Diabetes1 trial

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Terminated·UUniversity of Minnesota·Phase 1/2·NCT00672204·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Raptiva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raptiva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raptiva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

Raptiva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis6 trials

Sjogren's Syndrome1 trial

Discoid Lupus Erythematosus1 trial

CLE1 trial

Atopic Dermatitis1 trial

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News